149 related articles for article (PubMed ID: 30426567)
1. Impact of good and poor mobilizers on hematopoietic progenitor cell collection efficiency and product quality.
Azzouqa AM; Jouni K; Roy V; Zubair AC
J Clin Apher; 2019 Feb; 34(1):39-43. PubMed ID: 30426567
[TBL] [Abstract][Full Text] [Related]
2. Optia® continuous mononuclear collection (CMNC) system is a safe and efficient system for hematopoietic progenitor cells-apheresis (HPC-a) collection and yields a lower product hematocrit (HCT%) than the COBE® spectra system: A retrospective study.
Pandey S; Cottler-Fox M
J Clin Apher; 2018 Aug; 33(4):505-513. PubMed ID: 29603795
[TBL] [Abstract][Full Text] [Related]
3. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma.
Samaras P; Pfrommer S; Seifert B; Petrausch U; Mischo A; Schmidt A; Schanz U; Nair G; Bargetzi M; Taverna C; Stupp R; Stenner-Liewen F; Renner C
Biol Blood Marrow Transplant; 2015 Jan; 21(1):74-80. PubMed ID: 25278456
[TBL] [Abstract][Full Text] [Related]
5. Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells.
Vogel W; Kunert C; Blumenstengel K; Fricke HJ; Kath R; Sayer HG; Höffken K
J Cancer Res Clin Oncol; 1998; 124(6):341-5. PubMed ID: 9692843
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Hematopoietic Stem Cell Mobilization Rates with Early Plerixafor Administration for Adult Stem Cell Transplantation.
Stover JT; Shaw JR; Kuchibhatla M; Horwitz ME; Engemann AM
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1290-1294. PubMed ID: 28411174
[TBL] [Abstract][Full Text] [Related]
7. An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis.
Badar T; Dhakal B; Szabo A; Padmanabhan A; Johnson BD; Heidtke S; Esselmann J; Chhabra S; Hamadani M; Hari P; D'Souza A
J Clin Apher; 2019 Dec; 34(6):686-691. PubMed ID: 31566813
[TBL] [Abstract][Full Text] [Related]
8. Improved Prediction of CD34+ Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Value-Tailored Approach.
Sheppard D; Tay J; Palmer D; Xenocostas A; Doulaverakis C; Huebsch L; McDiarmid S; Tinmouth A; Mallick R; Martin L; Birch P; Hamelin L; Allan D; Bredeson C
Biol Blood Marrow Transplant; 2016 Apr; 22(4):763-767. PubMed ID: 26643030
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the predictive value of the hematopoietic progenitor cell count using an automated hematology analyzer for CD34+ stem cell mobilization and apheresis product yield.
Furundarena JR; Uranga A; Alkorta A; González C; Javier Ferreiro J; Rey M; Aragón L; Urreta I; Emparanza JI; Redín H; Garrido A; Araiz M
Int J Lab Hematol; 2020 Apr; 42(2):170-179. PubMed ID: 31830371
[TBL] [Abstract][Full Text] [Related]
10. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
11. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM
J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622
[TBL] [Abstract][Full Text] [Related]
12. How to manage poor mobilizers for high dose chemotherapy and autologous stem cell transplantation?
Ataca Atilla P; Bakanay Ozturk SM; Demirer T
Transfus Apher Sci; 2017 Apr; 56(2):190-198. PubMed ID: 28034547
[TBL] [Abstract][Full Text] [Related]
13. The use of plerixafor in hematopoietic progenitor cell collection in pediatric patients: a single center experience.
Pham HP; Patel N; Semedei-Pomales M; Bhatia M; Schwartz J
Cytotherapy; 2012 Apr; 14(4):467-72. PubMed ID: 22339604
[TBL] [Abstract][Full Text] [Related]
14. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.
Lee KH; Jung SK; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW; Kim DW; Kang ES
Vox Sang; 2014 Nov; 107(4):407-15. PubMed ID: 25130876
[TBL] [Abstract][Full Text] [Related]
15. Analysis of PBPC cell yields during large-volume leukapheresis of subjects with a poor mobilization response to filgrastim.
Moncada V; Bolan C; Yau YY; Leitman SF
Transfusion; 2003 Apr; 43(4):495-501. PubMed ID: 12662283
[TBL] [Abstract][Full Text] [Related]
16. An algorithm for utilizing peripheral blood CD34 count as a predictor of the need for plerixafor in autologous stem cell mobilization--cost-effectiveness analysis.
Abusin GA; Abu-Arja RF; Gingrich RD; Silverman MD; Zamba GK; Schlueter AJ
J Clin Apher; 2013 Aug; 28(4):293-300. PubMed ID: 23426644
[TBL] [Abstract][Full Text] [Related]
17. Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis.
Mohty M; Azar N; Chabannon C; Le Gouill S; Karlin L; Farina L; Milkovich G; Ostermann H; Glaß B; Noppeney R; Kron F; Kron A; Hübel K
Bone Marrow Transplant; 2018 Mar; 53(3):246-254. PubMed ID: 29255168
[TBL] [Abstract][Full Text] [Related]
18. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.
Pusic I; Jiang SY; Landua S; Uy GL; Rettig MP; Cashen AF; Westervelt P; Vij R; Abboud CN; Stockerl-Goldstein KE; Sempek DS; Smith AL; DiPersio JF
Biol Blood Marrow Transplant; 2008 Sep; 14(9):1045-1056. PubMed ID: 18721768
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of cells with engraftment capacity within CD34+ cell population upon G-CSF and Plerixafor mobilization.
Mombled M; Rodriguez L; Avalon M; Duchez P; Vlaski-Lafarge M; Debeissat C; Pérard B; Sawai KM; Pasquet JM; Bijou F; Thévenot F; Cabantous T; Ivanovic Z; Brunet de la Grange P
Leukemia; 2020 Dec; 34(12):3370-3381. PubMed ID: 32690879
[TBL] [Abstract][Full Text] [Related]
20. Plerixafor in poor stem cell mobilizers: the Belgian Compassionate Use Program.
Selleslag D; Dierickx D; Breems DA; Huynh P; Van De Velde A; Meers S; Brouwer E; Mertens A
Acta Clin Belg; 2011; 66(3):200-4. PubMed ID: 21837928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
